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A b s t r a c t
Serum and whole blood folate measurements are 
used lo establish folate deficiency. M ost methods used  
in clinical laboratories are automated, nonisotopic 
methods that use folate-binding protein.
Linearity, imprecision, and method comparison 
studies, including serum and whole blood liemolysates, 
were performed with the Access, Advia Centaur, 
A R C H IT E C T  i2000, Elecsys 2010, and IM M U LIT E  
20 0 0  methods. The QuantaPhase II radioassay served  
as the comparison method. (Proprietary information is 
given in the text.)
The A ccess and IM M U LIT E  2 0 0 0  methods had 
higher systematic errors in linearity studies than the 
other 3 methods. The imprecision o f  all methods was 
acceptable (coefficient o f  variation, < 1 0 % ) even al low  
folate concentrations with the exception o f  the Elecsys  
20 1 0  (coefficient o f  variation, 16% ). M ethod  
comparison studies using serum samples revealed 
calibration differences between the Access and Elecsys 
20 1 0  methods and the comparison method. M ethod  
comparison studies using whole blood samples showed  
poorer agreement between each o f  the automated 
methods and the comparison method than was seen 
with serum samples.
The A R C H IT E C T  i2000folate assay demonstrated 
the best analytic performance. The p oor agreement 
seen with whole blood liemolysates likely is due to 
calibration differences and differences in hemolysate 
preparation conditions.
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F olic  acid is a water-soluble vitamin that serves as a 
cofactor in 1-carbon transfers required for D N A replication. 
Its deficien cy  is associated with a m egaloblastic anemia. 
M ore recently, it has been o f  interest for the prevention o f  
neural tube defects and in homocysteine metabolism in the 
prevention o f  cardiovascular disease.1-4 Measurement o f  the 
serum or plasma folate concentration reflects recent dietary 
intake, while measurement o f  the erythrocyte folate concen­
tration is a better indicator o f  bod y  stores.5 A  number o f  
methods can be used to quantify folate, including m icrobio­
lo g ic  m ethods, assays using fo la te -b in d in g  protein , and 
v a r iou s  ch ro m a to g ra p h ic  te ch n iq u e s .6-9 M o st  current 
com m ercial assays use folate-binding protein with chemilu- 
minescence detection.10 The National Health and Nutrition 
Exam ination Survey, w hich was conducted from  1988 to 
1994, provides in form ation  on  the health and nutritional 
status o f  a wide cross-section o f  the US civilian population.11 
Samples included 23,378 serum folate determinations and 
23,082 RBC. folate determinations using the QuantaPhase II 
kit (Bio-Rad, Hercules, C A ), a radioassay, at the Centers for 
Disease Control and Prevention. The purpose o f  the present 
study was to evaluate how  current autom ated serum and 
whole b lood  folate assays perform and specifically to deter­
mine how they compare with the QuantaPhase II method.
M a t e r ia ls  a n d  M e t h o d s
Surplus serum and whole b lood  samples submitted for 
folate testing were obtained from  the clinical laboratory after 
clinical testing was complete. Both serum and whole b lood  
samples were stored for up to 2 weeks at -2 0 °C . A ll patient
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identifiers were removed, samples were divided into multiple 
aliquots, and aliquots were stored at ~70°C. until analysis. A ll 
aliquots were subjected to exactly the same handling proce­
dures before  analysis by  each method. A ll studies using 
samples from  human subjects were approved by the institu­
tion a l rev iew  b oa rd  o f  the U n iversity  o f  Utah H ealth  
Sciences Center (Salt Lake City).
The following automated methods and instruments were 
evaluated: the A ccess  (Beckm an Coulter, Brea, C A ), the 
Advia Centaur (Folate B A  method, Bayer Diagnostics, Tarry- 
town, N Y ), the A R C H IT E C T  i2000 (Abbott D iagnostics, 
Abbott Park, IL), the Elecsys 2010 (Roche Diagnostics, Indi­
anapolis, IN), and the IM M ULITE 2000 (Diagnostics Prod­
ucts, L os Angeles, C A ). The QuantaPhase II method was 
selected as the comparison method. A ll methods examined in 
the study are competitive, use folate-binding protein, were 
used accord ing  to their m anufacturers’ instructions, and 
required manual preparation o f  hemolysates for whole blood 
folate determinations. The hemolysate for the A ccess whole 
b lood folate method was prepared by making a 1:21 dilution 
o f  w hole b lo o d  w ith 0 .2 %  ascorb ic acid. For the A d v ia  
Centaur' method, a 1:21 dilution o f  whole b lood  was made 
w ith  1 .0%  a sco rb ic  acid . F or the A R C H IT E C T  i2 0 0 0  
method, a 1:11 dilution o f  whole b lood  was made with a solu­
tion containing 0.4%  ascorbic acid and guanidine hydrochlo­
ride. A  second 1:2 dilution with citric acid and guanidine 
hydrochloride was made before analysis. For the Elecsys 
2010 method, a 1:31 dilution o f  whole blood was made with 
0.2%  ascorbic acid. For the IM M ULITE 2000 method, a 1:5 
dilution o f  whole blood was made with 0.1%  ascorbic acid. 
For the QuantaPhase II method, a 1:11 dilution o f  whole 
blood was made with 0.4%  ascorbic acid, and a second 1:2 
dilution was made with assay diluent before analysis.
Linearity was assessed by preparing 2 serum pools by 
combining multiple patient samples, one with a low concen­
tration o f  folate and the other with a high concentration. The 
high p o o l was diluted with the low  p o o l to obtain final 
concentrations o f  the high pool o f  0% , 10%, 20% , 40% , 60% , 
80% , and 100% o f  the original. Each sample used to assess 
linearity was assayed in duplicate by each automated method. 
Assay imprecision was assessed by using 3 concentrations o f  
Lyphocheck quality control material (Bio-Rad Laboratories), 
which was reconstituted, multiple bottles were pooled, and 
aliquots for daily use were prepared and stored frozen at 
-7 0 °C  until used. Duplicate analyses were perform ed for 
each run, and 2 runs per day were performed on 5 days. EP 
Evaluator Release 4  software (David G. Rhoads Associates, 
Kennett Square, PA) was used for  com p lex  im precision  
calculations, Deming regression analysis, calculation o f  r and
S /3t, and linearity  assessm ent. F or D em in g  regression  
analysis, the im precision  o f  each m ethod, including the 
comparison method, was taken to be the same.
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The linearity o f  each method was evaluated by using 
pooled patient serum samples as described IFigure II. The 
slopes o f  the regression lines differed substantially between 
methods. The A ccess method had the lowest slope (13.9), 
and the A dvia Centaur' method had the highest slope (30.6). 
The A R C H IT E C T  i2000 and E lecsys 2010 m ethods had 
similar- slopes, while the slope o f  the IM M ULITE 2000 was 
slightly higher than these two. The target value for each 
linearity sample was calculated individually for each method 
by using the measured concentrations o f  the “ 0 % ”  pool and 
the highest linearity sample that fe ll within the analytic 
m easuring range. T he A d v ia  Centaur had a m axim um  
average deviation from  the target recovery o f  11 .4% ; the 
IM M ULITE 2000, 16.6%; and the Access, 22.1% . However, 
i f  an arbitrary 10% deviation limit from  the target values was 
used, on ly the A R C H IT E C T  i2000 (m axim um  deviation 
from  the target value, 4 .6 % ) and Elecsys 2010 (maximum 
deviation, 9 .6% ) methods would be deemed acceptable. The 
im precision  o f  each assay was assessed with com m ercial 
quality control materials ITable II. A ll methods except the 
E lecsys 2010 demonstrated total im precision  o f  less than 
10% , even at the low est folate concentration  exam ined, 
which fell in the folate-deficient range for serum.
M eth od  com pa rison  studies w ere p erform ed  using 
serum samples IFigure 21 and ITable 21. These demonstrated 
varying degrees o f  agreement with the comparison method, 
with slopes ranging from  0.60 to 0.99 and correlation coeffi­
cients o f  0.83 to 0.95. The differences in slope may be due to 
calibration issues. The A ccess method had a slope o f  0.60 
com pared with the QuantaPhase II com parison method. It 
also demonstrated 1 point that was a statistical outlier even 
after repeated testing. The reason for this discordant result 
that was unique to the A cce ss  m ethod is unknown. The 
E lecsys 2010  m ethod had a slope o f  0 .76 relative to the 
com parison  m ethod. This cou ld  be due to a calibration  
difference; however, the linearity study shown in Figure ID  
does not support this hypothesis. It also is noteworthy that 
the dispersion o f  data around the regression line as reflected 
in either the correlation coefficient or the SE o f  the estimate 
is less than desirable. The A R C H IT E C T  i2 00 0  m ethod 
demonstrated the best overall agreement with the com par­
ison method.
M eth od  com pa rison  studies w ere p erform ed  using 
w hole b lood  samples IFigure 31 (Table 2) and, in general, 
showed poorer agreement with the comparison method than 
was seen with serum samples. The calibration difference 
seen with the A ccess method for serum was not confirmed 
with whole b lood  samples, which gave a slope o f  1.34. The 
A dvia Centaur method had a slope o f  1.20 compared with 
the com parison method. The A R C H IT E C T  i2000 method
R esu lts
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IFigure II Linearity of automated serum folate methods. Aliquots of the sam e serum samples were used for each method. The 
solid lines are linear regression analysis. A , Evaluation of the A ccess method. Linear regression analysis gave a slope of 13.9, an 
intercept of 2.13 pg/L, and r=  0.994. B, Evaluation of the Advia Centaur method. Linear regression analysis gave a slope of 
30.6, an intercept of 2.41 pg/L, and r=  0.992. C, Evaluation of the ARCHITECT i2000 method. Linear regression analysis gave a 
slope of 21.5, an intercept of 1.38 pg/L, and r=  0.999. D, Evaluation of the Elecsys 2010 method. Linear regression analysis 
gave a slope of 20.8, an intercept of 1.92 pg/L, and r=  0.996. E, Evaluation of the IMMULITE 2000 method. Linear regression 
analysis gave a slope of 24.5, an intercept of 2.37 pg/L, and r = 0.996. For proprietary information, see  the text.
also had a negative intercept ( -3 9 ) blit a slope o f  1.06. The 
E lecsys 2010 method had a slope o f  1.88 and a negative 
intercept (-2 7 ). The IM M U LITE 2000 had a slope o f  2.99 
but a large negative intercept (-14 1 ). Correlation coefficients 
for all methods were higher than for  serum samples. The 
AR CH ITEC T i2000 method performed die best o f  the auto­
mated methods evaluated in this study for w hole blood folate 
determinations.
D i s c u s s i o n
O f the 5 automated folate m ethods evaluated in this 
study, the A R C H IT E C T  i2000 and E lecsys 2010 dem on­
strated the best linearity w ith recoveries for  each  point 
falling within ±10%  o f  the target value. The lineaiity o f  the 
A dvia Centaur method was slightly worse. The A ccess and 
IM M U LITE 2000 methods had higher deviations from  ideal
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recoveries than the other 3 methods. The lack o f  lineaiity 
exhibited by the A ccess method, although similar in some 
respects , is m uch less pron ou n ced  than what has been  
published for the A x S Y M  folate method.12'13 The impreci­
sion o f  all methods was acceptable with coefficients o f  varia­
tion o f  less than 10%, even at low folate concentrations, with 
the exception o f  the Elecsys 2010 method. It had an overall 
im precision  o f  16% at the low est concentration o f  folate 
examined. M ethod comparison studies using serum samples 
revealed substantial calibration differences between some o f  
the automated methods and the QuantaPhase II comparison 
method. The A ccess method yielded lower results for patient 
serum samples compared with the QuantaPhase II method. 
This presumed difference in calibration is reflected in the 
linearity  sam ples (F igure IA )  but not in the m eans o f  
repeated analysis o f  quality control material (Table 1). This 
may reflect a matrix effect with the control materials. The 
Elecsys 2010 method also yielded low er results compared
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ITable II
Summary of Imprecision Data
Method* Level'
Folate Concentration (ng/L) Coefficient of Variation (%)
M ean Target Mean* W ithin Run Total
Access 1 2.2 2.2 7.7 9.9
2 6.0 5.8 1.6 3.8
3 11.7 11.1 2.4 5.9
Advia Centaur 1 2.4 2.3 5.4 8.0
2 5.5 5.7 2.5 6.4
3 9.3 9.9 4.4 8.0
ARCHITECT I2000 1 2.1 2.1 8.2 8.4
2 4.6 5.0 2.8 4.2
3 9.9 11.1 1.0 2.3
Elecsys 2010 1 1.7 2.2 9.9 16.0
2 3.8 4.4 3.6 11.6
3 6.6 7.3 2.9 7.0
IMMULITE 2000 1 2.0 2.0 4.5 8.8
2 6.5 5.9 3.3 7.5
3 12.3 11.1 2.0 4.8
* For proprietary information, see the text.
T Level 1 corresponded to lot number 40121, level 2 to lot number 40122, and level 3 to lot number 40123. Together these constitute lot 40120.
* The target mean folate concentration was the cumulative mean from the Unity Worldwide Report for Immunoassay Plus provided by Bio-Rad Laboratories (Hercules, CA) for 
November 2002 for lot 40120. This information serves to confirm that each of the methods was calibrated in a manner consistent with what would be expected based on data 
from multiple clinical laboratories.
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IFigure 21 Comparison of autom ated serum  folate m ethods (A, Access; B, Advia Centaur; C, ARCHITECT i2000; D, Elecsys 
2010; E, IMMULITE 2000) with the Q uantaPhase II comparison method. The solid lines are from Deming regression, and the 
dashed lines are x = y. Unless otherw ise indicated, 83 sam ples w ere included in the analysis. In the comparison of the Access 
method (A), 1 outlier, indicated by an open circle, was excluded from further analysis. The regression statistics are given in 
Table 2. For proprietary information, se e  the text.
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ITable 21
Summary of Deming Regression Statistics for Serum and Whole Blood Samples
Method Sample Type Slope Y Intercept (jig/L) SE of the Estimate (jig/L) r
Access Serum 0.60 ± 0.04 1.17 ± 0.40 1.68 0.858
W hole blood 1.34 ± 0.08 17 ± 16 40 0.940
ADVIA Centaur Serum 0.95 ± 0.06 0.83 ± 0.66 2.78 0.833
W hole blood 1.20 ± 0.15 79 + 29 76 0.725
ARCHITECT i2000 Serum 0.99 ± 0.03 -0 .9 4  + 0.37 1.58 0.950
W hole blood 1.06 ± 0.06 -3 9 +  11 28 0.954
Elecsys 2010 Serum 0.76 ± 0.05 -0 .4 2  + 0.54 2.27 0.835
W hole blood 1.88 + 0.11 -2 7  + 21 54 0.944
IMMULITE 2000 Serum 0.96 ± 0.05 0.32 + 0.55 2.32 0.887
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IFigure 31 Comparison of autom ated whole blood folate m ethods (A, Access; B, Advia Centaur; C, ARCHITECT i2000; D, 
Elecsys 2010; E, IMMULITE 2000) with the QuantaPhase II comparison method. The solid lines are from Deming regression, 
and the dashed lines are x = y. A total of 37 sam ples w ere included in the analysis. The regression statistics are given in Table
2. For proprietary information, see  the text.
with the QuantaPhase II method. The results of repeated 
analysis of quality control material (Table 1) reflect this 
presumed calibration difference, while the linearity sample 
(Figure ID) does not. The basis for these differences is 
uncertain. The agreement between these 2 methods was 
better than that between either one and the comparison 
method (data not shown). Additional calibration standardiza­
tion efforts seem to be required for some of these methods.
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Previous studies examining folate assay performance 
found higher overall variability for whole blood results 
compared with results for serum samples.7 Some possible 
reasons for the generally poorer folate method comparisons 
seen with whole blood samples have been described previ­
ously. Folate can be trapped irreversibly by oxyhemo­
globin.14 It has been suggested that hemoglobin can irre­
versibly denature at low pH (<5.0) and trap folate, although
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this is controversial.15-16 Furthermore, incomplete lysis of 
RBCs also can contribute to underrecovery of folate. More 
complete hemolysis can be obtained by the addition of 
saponin or Triton X-100 nonionic detergent.15-16 A careful 
review of the manufacturer-specified conditions used to 
prepare whole blood liemolysates for each of the methods 
showed that a range of ascorbic acid concentrations and dilu­
tion factors were recommended. The whole blood folate 
method com parison betw een the Elecsys 2010 and 
IMMULITE 2000 methods and QuantaPhase 11 comparison 
method demonstrated substantially higher results for both, 
while with serum samples the 2 methods were comparable. 
The reason for this apparent overrecovery with whole blood 
samples is unclear. The ARCHITECT i2000 method demon­
strated the best agreement with the comparison method. 
Both this method and the QuantaPhase 11 comparison 
method required a 1:11 dilution with 0.4% ascorbic acid for 
initial hemolysis preparation followed by a second 1:2 dilu­
tion. This may, at least in part, explain the good agreement 
seen for these 2 methods. It is noteworthy that hemolysate 
for the ARCHITECT i2000 method also contained guani­
dine hydrochloride and citric acid. The role of these agents is 
unknown.
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